A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15308510.
- Also identified by PMC identifier 1755145.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Evidence suggests that endothelin may have a fundamental role in scleroderma pathogenesis, including pulmonary arterial hypertension (PAH)--a leading cause of death in patients with scleroderma. Development of a new class of drug, endothelin receptor antagonists, heralds an improved outlook for patients with scleroderma and related diseases. Heightened vigilance towards early detection of PAH in scleroderma and a multidisciplinary approach to diagnosis and treatment may improve clinical outcomes for these patients.
Medical subject headings
- Antihypertensive Agents
- Endothelin Receptor Antagonists
- Hypertension, Pulmonary
- Scleroderma, Systemic